Evaluate the Efficacy of Armodafinil for Patients With B-cell Lymphoma and Severe Fatigue

The Washington University

Status: Withdrawn

Conditions: B-cell Lymphoma; Fatigue

Treatments: Drug: Armodafinil; Drug: placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT01044004

09-1896

Details and patient eligibility

About

To determine whether armodafinil is more effective than placebo in reducing fatigue.

Full description

Aims will be analyzed separately as stratified by treatment arm (chemotherapy treatment arm vs. post-treatment remission arm).

Primary Objective:

• To determine whether armodafinil is more effective than placebo in reducing fatigue as measured by the change in scores from the FACT-Fatigue reported at study entry, week 7 of study treatment, and study completion (week 13).

Secondary Objectives:

• To determine whether armodafinil is more effective than placebo in reducing fatigue as measured by standard actigraphy summary statistics including total sleep time (TST), wake after sleep onset (WASO), sleep latency, number of awakenings, daytime sleep time, mean daytime activity, peak activity, acrophase, and circadian mesor at week 1 of screening, week 7 of study treatment, and study completion (week 13).
• To determine whether armodafinil is more effective than placebo in improving work quality as measured by the change in scores from the WLQ© reported at study entry (week 1) and study completion (week 13).
• To determine whether armodafinil is more effective than placebo in reducing fatigue as measured by the change in activity patterns with actigraphy using applied functional data analysis during week 1 of screening, week 7 of study treatment, and study completion (week 13).
• To evaluate whether measured cytokines (IL-2, IL-6, IL-10, TNF-α, and TGF-α) are elevated at baseline.
• To evaluate whether measured cytokines (IL-2, IL-6, IL-10, TNF-α, and TGF-α) change from the time of study entry to study completion.
• To assess whether cytokine levels (IL-2, IL-6, IL-10, TNF-α, and TGF-α) correlate with circadian patterns in wrist actigraphy and self-described reports of fatigue as measured by the FACT-Fatigue at baseline and study completion.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria for both arms:

• Age ≥ 18 with diagnosis of B-cell lymphoma
• Average score of ≥ 7 on daily worst fatigue severity assessment from the BFI questionnaire during screening
• Able to demonstrate appropriate use of the wrist actigraphy device and to complete questionnaires
• ECOG performance status 0-2
• Laboratory values:
• Hemoglobin ≥ 10 g/dL
• Total Bilirubin ≤ 1.5 x institutional ULN
• AST/ALT ≤ 2.5 x institutional ULN
• Creatinine ≤ 1.5 x institutional ULN
• Albumin ≥ 3.5 g/dl
• Life expectancy > 6 months
• IRB-approved informed consent form must be signed before any protocol-specific screening procedures are performed.

Inclusion criteria for patients undergoing R-CHOP chemotherapy:

• Scheduled to receive 6 cycles of standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy as first-line treatment

Inclusion criteria for patients in remission following chemotherapy and/or radiotherapy:

• May have received one prior regimen of chemotherapy and/or radiotherapy

• Adequate response to upfront chemotherapy and/or radiotherapy

• Indolent lymphomas - must have achieved a partial or complete response with no immediate plans for further treatment

• Aggressive lymphomas - must have achieved a complete response:

  • ≥ 4 weeks since completion of chemotherapy
  • ≥ 8 weeks since completion of radiotherapy
  • ≤ 18 months since completion of chemotherapy or radiotherapy

Exclusion Criteria for both arms:

• Uncontrolled medical and/or psychiatric condition that may cause fatigue or that the PI feels is clinically significant and might adversely affect patient safety (such as sleep disorders, moderate/severe depression, metabolic/endocrine abnormalities, infections)
• History of clinically significant cardiac disorders, such as left ventricular hypertrophy or mitral valve prolapse experienced in conjunction with receiving CNS stimulants
• History of serious skin reactions, such as serious rash or Stevens-Johnson Syndrome
• Concurrent stimulant medication
• Any other active malignancy within the past 3 years except cervical carcinoma in situ and non-melanoma skin cancers
• Known CNS involvement by lymphoma
• Cachexia
• Use of opioids at time of randomization
• Known sensitivity to modafinil and/or armodafinil

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind

---

0 participants in 4 patient groups, including a placebo group

Post treatment remission armodafinil

Experimental group

Description:

Armodafinil 150 mg/day for 13 weeks

Treatment:

Drug: Armodafinil

Drug: Armodafinil

Post treatment remission placebo

Placebo Comparator group

Description:

Placebo 150mg/day for 13 weeks

Treatment:

Drug: placebo

Drug: placebo

Chemotherapy armodafinil

Experimental group

Description:

Armodafinil 150 mg/day for 13 weeks

Treatment:

Drug: Armodafinil

Drug: Armodafinil

Chemotherapy placebo

Placebo Comparator group

Description:

Placebo 150mg/day for 13 weeks

Treatment:

Drug: placebo

Drug: placebo